
Amplyx Pharmaceuticals was a San Diego-based clinical-stage biopharmaceutical company founded in 2006 on a mission to save lives by developing a novel class of antifungal medicines to overcome the severe limitations of existing treatments. Its lead compound, fosmanogepix (APX001), represented a first-in-class antifungal mechanism targeting the Gwt1 enzyme. In April 2021, Amplyx was acquired by Pfizer Inc., which continued development of fosmanogepix as part of its infectious disease pipeline.
Create a free account to see funding visualizations and detailed round data.
Create Free AccountCreate a free account to see full funding history, valuations, and investor participation.
Create Free AccountCreate a free account to see which investors have funded this company.
Create Free Account